Therefore, properly adjusting the dosage of erythropoietin in patients with ESRD anemia, slowly increasing the concentration of hemoglobin in patients with MHD, and maintaining it at an appropriate level have important clinical significance for the prevention of arteriovenous fistula embolism. This evidence concerns the gene EPO and anemia (phenotype).